Nothing Special   »   [go: up one dir, main page]

CO6362022A2 - COMPLETELY HUMAN ANTIBODIES AGAINST N-CADHERINE - Google Patents

COMPLETELY HUMAN ANTIBODIES AGAINST N-CADHERINE

Info

Publication number
CO6362022A2
CO6362022A2 CO11070983A CO11070983A CO6362022A2 CO 6362022 A2 CO6362022 A2 CO 6362022A2 CO 11070983 A CO11070983 A CO 11070983A CO 11070983 A CO11070983 A CO 11070983A CO 6362022 A2 CO6362022 A2 CO 6362022A2
Authority
CO
Colombia
Prior art keywords
cadherin
antibodies
cadherine
human antibodies
fragments
Prior art date
Application number
CO11070983A
Other languages
Spanish (es)
Inventor
Robert Reiter
Eric Lepin
Anna M Wu
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of CO6362022A2 publication Critical patent/CO6362022A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70525—ICAM molecules, e.g. CD50, CD54, CD102

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)

Abstract

La presente solicitud de patente provee anticuerpos y sus fragmentos, que incluyen anticuerpos completamente humanos y sus fragmentos, que son capaces de unirse a un dominio extracelular de N-cadherina. Los anticuerpos son útiles en el diagnóstico y en el tratamiento de cánceres que expresan o sobreexpresan N-cadherina. Por ejemplo, la solicitud de patente provee anticuerpos monoclonales, o fragmentos de ellos, que son capaces de unirse a los dominios extracelulares 1-3- de N-cadherina y que son útiles en el diagnóstico o el tratamiento de un cáncer de próstata o de vejiga humano que expresa o sobre expresa N-cadherina.The present patent application provides antibodies and their fragments, which include fully human antibodies and their fragments, which are capable of binding to an extracellular domain of N-cadherin. Antibodies are useful in the diagnosis and treatment of cancers that express or overexpress N-cadherin. For example, the patent application provides monoclonal antibodies, or fragments thereof, that are capable of binding to the extracellular domains 1-3- of N-cadherin and that are useful in the diagnosis or treatment of prostate cancer or Human bladder expressing or expressing N-cadherin.

CO11070983A 2008-11-10 2011-06-08 COMPLETELY HUMAN ANTIBODIES AGAINST N-CADHERINE CO6362022A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11304208P 2008-11-10 2008-11-10

Publications (1)

Publication Number Publication Date
CO6362022A2 true CO6362022A2 (en) 2012-01-20

Family

ID=42153647

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11070983A CO6362022A2 (en) 2008-11-10 2011-06-08 COMPLETELY HUMAN ANTIBODIES AGAINST N-CADHERINE

Country Status (13)

Country Link
US (2) US8703920B2 (en)
EP (1) EP2356145A4 (en)
JP (1) JP2012508027A (en)
KR (1) KR20110084309A (en)
CN (1) CN102300873A (en)
AU (1) AU2009313239A1 (en)
BR (1) BRPI0921457A2 (en)
CA (1) CA2743122A1 (en)
CO (1) CO6362022A2 (en)
IL (1) IL212795A0 (en)
MX (1) MX2011004945A (en)
RU (1) RU2011123655A (en)
WO (1) WO2010054377A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090130108A1 (en) * 2006-03-21 2009-05-21 The Regents Of The University Of California N-Cadherin and Ly6 E: Targets for Cancer Diagnosis and Therapy
US8663635B2 (en) * 2006-03-21 2014-03-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
MX2010010835A (en) * 2008-04-04 2011-02-22 Univ California Novel antibodies against cancer target block tumor growth, angiogenesis and metastasis.
US8703920B2 (en) 2008-11-10 2014-04-22 The Regents Of The University Of California Fully human antibodies against N-cadherin
GB201119089D0 (en) 2011-11-04 2011-12-21 Isis Innovation Treatment of musculoskeletal fibroproliferative disorders
CN104203280A (en) 2012-03-27 2014-12-10 诺华股份有限公司 Treatment of fibrosis
WO2016028663A1 (en) * 2014-08-21 2016-02-25 Johnson Controls Technology Company Battery monitoring system
US20200165351A1 (en) * 2017-06-06 2020-05-28 The Regents Of The University Of California Humanized anti-n-cadherin antibodies and uses thereof
WO2022237874A1 (en) * 2021-05-13 2022-11-17 Wuxi Biologics (Shanghai) Co., Ltd. Antibody conjugate comprising anti-p-cadherin antibody and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889157A (en) * 1990-10-12 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Humanized B3 antibody fragments, fusion proteins, and uses thereof
AU669124B2 (en) * 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US6680175B2 (en) 1998-05-05 2004-01-20 Adherex Technologies, Inc. Methods for diagnosing and evaluating cancer
US6277824B1 (en) * 1998-07-10 2001-08-21 Adherex Technologies Compounds and methods for modulating adhesion molecule function
AU2001249064A1 (en) 2000-02-22 2001-09-03 Mount Sinai School Of Medicine Of New York University N-cadherin modulated migration, invasion, and metastasis
US20030190602A1 (en) * 2001-03-12 2003-10-09 Monogen, Inc. Cell-based detection and differentiation of disease states
DE602004025101D1 (en) * 2003-05-31 2010-03-04 Micromet Ag HUMAN ANTI-HUMANE CD3 BONDING MOLECULES
WO2005097184A2 (en) * 2004-03-26 2005-10-20 Human Genome Sciences, Inc. Antibodies against nogo receptor
WO2006138275A2 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20100278821A1 (en) * 2006-03-21 2010-11-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
US8663635B2 (en) 2006-03-21 2014-03-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
US20090130108A1 (en) 2006-03-21 2009-05-21 The Regents Of The University Of California N-Cadherin and Ly6 E: Targets for Cancer Diagnosis and Therapy
MX2010010835A (en) * 2008-04-04 2011-02-22 Univ California Novel antibodies against cancer target block tumor growth, angiogenesis and metastasis.
US8703920B2 (en) 2008-11-10 2014-04-22 The Regents Of The University Of California Fully human antibodies against N-cadherin

Also Published As

Publication number Publication date
WO2010054377A3 (en) 2010-09-16
CN102300873A (en) 2011-12-28
BRPI0921457A2 (en) 2016-01-12
US20140017240A1 (en) 2014-01-16
WO2010054377A2 (en) 2010-05-14
CA2743122A1 (en) 2010-05-14
AU2009313239A1 (en) 2011-07-07
WO2010054377A9 (en) 2011-02-03
US20100233170A1 (en) 2010-09-16
RU2011123655A (en) 2012-12-20
MX2011004945A (en) 2011-11-01
US8703920B2 (en) 2014-04-22
JP2012508027A (en) 2012-04-05
EP2356145A4 (en) 2012-07-18
EP2356145A2 (en) 2011-08-17
KR20110084309A (en) 2011-07-21
IL212795A0 (en) 2011-07-31

Similar Documents

Publication Publication Date Title
CO6362022A2 (en) COMPLETELY HUMAN ANTIBODIES AGAINST N-CADHERINE
CY1122816T1 (en) TARGETED BINDING AGENTS AGAINST B7-H1
CY1120913T1 (en) MONOCLONIC ANTIBODIES AGAINST PROGASTRIN AND THEIR USE
PH12019500438A1 (en) Anti-gcc antibody molecules and related compositions and methods
PH12020551689A1 (en) Her2-targeting antigen binding molecules comprising 4-1bbl
UY32061A (en) HUMAN ANTIBODIES FOR HUMAN RANKL
CL2007003622A1 (en) Human anti-cd19 monoclonal antibody; composition comprising it; and tumor cell growth inhibition method.
UY33826A (en) UNION PROTEINS WITH TRIVARIABLE DOMAINS AND ITS USES
GT201200109A (en) IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
BRPI0719202A2 (en) Diagnosis and treatment of cancer using antiereg antibody
AR077866A1 (en) COMBINATION THERAPY OF A CD20 AFUCOSILATED AND BENDAMUSTINE ANTIBODY
UY35468A (en) CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER
HK1243943A1 (en) TREATMENT OF CANCER WITH ANTI-IL-1α ANTIBODIES
UY30525A1 (en) DIRECTED UNION AGENTS WHOSE WHITE IS THE PDGFR-ALFA AND ITS USES
MX337600B (en) J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use.
CY1112739T1 (en) ANTI-CD79B ANTIBODIES AND IMMUNIZATIONS AND METHODS OF USE
ECSP12012309A (en) ANTIBODIES TO GDF8 HUMAN
MX340724B (en) Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer.
MX2019015352A (en) Ror1 car t-cells.
AR077867A1 (en) COMBINATORY THERAPY OF A CD20 ANTIBODY AFUCOSILATED WITH FLUDARABINE AND / OR MITOXANTRONE
NZ607588A (en) Antibodies against human TWEAK and uses thereof
DK3423496T3 (en) Non-antagonistic antibodies targeting the alpha chain of the IL7 receptor's extracellular domain and its use in cancer therapy
AR071304A1 (en) ANTIBODIES ANTI CD151 (FLBR MEMBRANE PROTEIN. OF TETRASPANINS) USEFUL FOR CANCER TREATMENT
BR112015027474A8 (en) antibody, composition, method of treatment of the cancer patient and use of an antibody.
CL2008003525A1 (en) Human anti-rg1 monoclonal antibody conjugate or an antigen-binding portion thereof with associated molecules, which composition comprises; in vitro method for inhibiting the growth of a tumor cell expressing rg-1; use of this conjugate to treat cancer

Legal Events

Date Code Title Description
FA Application withdrawn